Stock TNXP TONIX PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

News Tonix Pharmaceuticals Nasdaq

Equities

TNXP

US8902608624

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
0.3222 USD -2.36% Intraday chart for Tonix Pharmaceuticals +2.32% -20.05%
Apr. 01 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Apr. 01 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
AQ
Tonix Pharmaceuticals : Investor Presentation April 2024
PU
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID
PU
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
AQ
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble
MT
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
AQ
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome
MT
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
AQ
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
AQ
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting
CI
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
AQ
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
AQ
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID
PU
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
AQ
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial
CI
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
AQ
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia
AQ
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNXP Stock
  4. TNXP Stock
  5. News Tonix Pharmaceuticals